This is an observational, retrospective-prospective, multicentre trial enrolling all patients included in the AIFA monitoring registry of Dostarlimab for the indication in rectal cancer. The aims of the study are to describe the clinical outcomes and safety of patients with dMMR/MSI-H locally advanced rectal cancer (LARC) receiving neoadjuvant dostarlimab in the real-world setting.
Signed informed consent form
Age > 18 years
Histologically confirmed stage II-III rectal cancer
dMMR/MSI status assessed locally by Immunohistochemistry, next-generation sequencing or PCR
- Distant metastasis
Major cognitive dysfunction or psychiatric disorders
Any previous systemic or local treatment for rectal cancer
Dostarlimab received within an interventional clinical trial